Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Justice Department sues to block UnitedHealth Group’s $13 billion acquisition of Change Healthcare

The Department of Justice has filed a civil lawsuit to stop the $13 billion merger between UnitedHealth Group and Change Healthcare.

The complaint was filed today by the DOJ and Attorneys General in Minnesota and New York, in the U.S. District Court for the District of Columbia.

As alleged in the complaint, the proposed transaction would give United, a company that owns the largest health insurer in the United States, access to a vast amount of its rival health insurers’ competitively sensitive information, according to the DOJ.

The proposed transaction would harm competition in commercial health insurance markets, as well as in the market for technology used by health insurers to process health insurance claims, the DOJ said. It would give United control of a critical data highway of health insurance claims.

Source: Healthcare Finance

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!